ROS kinase in lung cancer
US11099188B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 31, 2018 |
| Grant date | Aug 24, 2021 |
| Priority date | — |
| Expiry date | May 31, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/912
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of ROS are described, namely proteins encoded by the FIG gene, the SLC34A2 gene, and the CD74 gene. The invention enables new methods for determining the presence of a polypeptide with ROS kinase activity in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer (e.g., an lung cancer).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.